Compare NUAI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUAI | CABA |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 212.7M |
| IPO Year | N/A | 2019 |
| Metric | NUAI | CABA |
|---|---|---|
| Price | $4.61 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | ★ 7.5M | 4.3M |
| Earning Date | 03-31-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $843,029.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.89 | N/A |
| 52 Week Low | $0.32 | $0.99 |
| 52 Week High | $9.45 | $3.67 |
| Indicator | NUAI | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 58.18 |
| Support Level | $4.78 | $2.29 |
| Resistance Level | $5.39 | $2.69 |
| Average True Range (ATR) | 1.00 | 0.21 |
| MACD | -0.30 | -0.00 |
| Stochastic Oscillator | 0.26 | 55.49 |
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.